Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CIDARA THERAPEUTICS, INC.

(CDTX)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
0.6701 USD   -8.18%
09/20Cidara Therapeutics Gets Priority Review for Rezafungin -- Stock Up 5% After-Hours
MT
09/20Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
GL
09/20Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about CIDARA THERAPEUTICS, INC.
09/20Cidara Therapeutics Gets Priority Review for Rezafungin -- Stock Up 5% After-Hours
MT
09/20Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Applicatio..
GL
09/20Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Appl..
CI
09/20Cidara Therapeutics Shares Rise 7.1% on Rezafungin FDA Priority Review
DJ
09/13Cidara Therapeutics Starts Phase 2a Trial of Antiviral CD388 in Influenza
MT
09/13Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Eva..
GL
09/13Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Eva..
CI
09/08Cidara Therapeutics Chief Operating Officer Paul Daruwala Resigns, Successor Named
MT
09/08Cidara Therapeutics, Inc. Announces Executive Changes
CI
09/06Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Con..
GL
08/09CIDARA THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/09CIDARA THERAPEUTICS : Quarterly Report for Quarter Ending JUNE 30, 2022 (Form 10-Q)
PU
08/09CIDARA THERAPEUTICS : Provides Corporate Update and Reports Second Quarter 2022 Financial ..
PU
08/09Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial..
GL
08/09Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial..
GL
More most relevant news
All news about CIDARA THERAPEUTICS, INC.
09/20Cidara Therapeutics Gets Priority Review for Rezafungin -- Stock Up 5% After-Hours
MT
09/20Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Applicatio..
GL
09/20Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Appl..
CI
09/20Cidara Therapeutics Shares Rise 7.1% on Rezafungin FDA Priority Review
DJ
09/13Cidara Therapeutics Starts Phase 2a Trial of Antiviral CD388 in Influenza
MT
09/13Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Eva..
GL
09/13Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Eva..
CI
09/08Cidara Therapeutics Chief Operating Officer Paul Daruwala Resigns, Successor Named
MT
09/08CIDARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/08Cidara Therapeutics, Inc. Announces Executive Changes
CI
More news
News in other languages on CIDARA THERAPEUTICS, INC.
09/20Cidara Therapeutics obtient une évaluation prioritaire pour la rezafungine -- L'action ..
09/20Cidara Therapeutics, Inc. annonce l'acceptation par la FDA de l'examen prioritaire de l..
09/13Cidara Therapeutics lance un essai de phase 2a de l'antiviral CD388 dans la grippe
09/13Cidara Therapeutics annonce le lancement d'un essai de provocation virale humaine de ph..
09/08Le directeur de l'exploitation de Cidara Therapeutics, Paul Daruwala, démissionne, son ..
09/08Cidara Therapeutics, Inc. annonce des changements de direction
08/09Earnings Flash (CDTX) CIDARA THERAPEUTICS affiche un chiffre d'affaires de 6,2 millions..
08/09Cidara Therapeutics, Inc. annonce ses résultats pour le deuxième trimestre et le semest..
07/27Cidara Therapeutics soumet à la FDA une demande d'autorisation de mise sur le marché d'..
07/27Cidara Therapeutics, Inc. soumet une demande de nouveau médicament à la Food and Drug A..
More news
Analyst Recommendations on CIDARA THERAPEUTICS, INC.
07/15Wedbush Drops Coverage of Cidara Therapeutics
MT
05/12HC Wainwright Adjusts Cidara Therapeutics Price Target to $6 From $7.50, Maintains Buy ..
MT
02/02Maxim Group Adjusts Cidara Therapeutics Price Target to $3 From $5, Maintains Buy Ratin..
MT
2021Wedbush Lifts Cidara Therapeutics' Price Target to $6 From $5 on Echinocandin Rezafungi..
MT
2021CIDARA THERAPEUTICS : Aegis Capital Adjusts Cidara Therapeutics PT to $8 From $9, Maintain..
MT
More recommendations
Press releases
09/20Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Applicatio..
GL
09/13Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Eva..
GL
09/08CIDARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/06Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Con..
GL
09/02CIDARA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
More press releases
Upcoming event on CIDARA THERAPEUTICS, INC.